MissionIR Articles
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its abstract was…
-
National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
A simple search of the Internet shows a number of clinical trials attempting to improve treatment options for glioblastoma (“GBM”) brain cancers, and Congress will recognize a National Glioblastoma Awareness Day next month to further…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in the Virtual Investor Summer Spotlight…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in an upcoming webcast fireside chat.…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced that its ongoing…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Bettina M. Cockroft, M.D.,…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Retains Analytics Firm, Investigates Possible Naked Short Selling
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is investigating potential naked short selling of its stock.…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate, Present at Upcoming Virtual Investor Spotlight Event
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor Spotlight…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial
CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer
For decades, medical science has sought an effective means of stopping the most common primary brain cancer in adults in its tracks and keeping it from recurring. In spite of multimodal treatment that includes surgical…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Its Potentially Pivotal Global GBM Trial, Reports No Exposure to SVB Issues
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently reported the enrolment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls Over 100 Patients in Potentially Pivotal Berubicin Study
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that more than 100 patients have been…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Adds Italy to Growing Portfolio of Countries for Berubicin Study
CNS Pharmaceuticals (NASDAQ: CNSP) today announced its receipt of approval from the Italian Medicines Agency (“AIFA”) Competent Authority and the A.O.U. Policlinico di Bari Ethics Committee for its ongoing potentially pivotal global trial evaluating Berubicin…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces FY 2022 Results, Corporate Update
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the full year…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM…
Search Articles
Latest Articles
- A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Advancing Retail Innovation Through AI-Powered Smart-Cart Technology
- Forward Industries Inc. (NASDAQ: FWDI) Positive Update for Shareholders After Debuting the Company’s Solana Treasury Strategy
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures Funding to Strengthen North American Supply Chain
- MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast